Fundamental Analysis of RHYTHM PHARMACEUTICALS INC(NASDAQ:RYTM) stock

Fundamental Rating

Taking everything into account, RYTM scores 2 out of 10 in our fundamental rating. RYTM was compared to 587 industry peers in the Biotechnology industry. RYTM may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, RYTM is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year RYTM has reported negative net income.

RYTM had a negative operating cash flow in the past year.

RYTM had negative earnings in each of the past 5 years.

In the past 5 years RYTM always reported negative operating cash flow.

1.2 Ratios

RYTM has a worse Return On Assets (-105.88%) than 79.49% of its industry peers.

RYTM has a worse Return On Equity (-444.72%) than 77.61% of its industry peers.

		Industry Rank	Sector Rank
ROA	-105.88%
ROE	-444.72%
ROIC	N/A

ROA(3y)-41.33%

ROA(5y)-48.24%

ROE(3y)-67.27%

ROE(5y)-66.47%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 88.38%, RYTM belongs to the best of the industry, outperforming 91.97% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	88.38%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.

RYTM has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, RYTM has more shares outstanding

Compared to 1 year ago, RYTM has a worse debt to assets ratio.

2.2 Solvency

RYTM has an Altman-Z score of -0.53. This is a bad value and indicates that RYTM is not financially healthy and even has some risk of bankruptcy.

RYTM has a Altman-Z score (-0.53) which is comparable to the rest of the industry.

A Debt/Equity ratio of 1.74 is on the high side and indicates that RYTM has dependencies on debt financing.

RYTM has a Debt to Equity ratio of 1.74. This is amonst the worse of the industry: RYTM underperforms 81.03% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.74
Debt/FCF	N/A
Altman-Z	-0.53

ROIC/WACCN/A

WACC8.81%

2.3 Liquidity

RYTM has a Current Ratio of 4.35. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.

RYTM has a Current ratio (4.35) which is in line with its industry peers.

RYTM has a Quick Ratio of 4.20. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 4.20, RYTM is in line with its industry, outperforming 48.03% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.35
Quick Ratio	4.2

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for RYTM have decreased strongly by -38.21% in the last year.

RYTM shows a strong growth in Revenue. In the last year, the Revenue has grown by 173.49%.

EPS 1Y (TTM)-38.21%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-155.43%

Revenue 1Y (TTM)173.49%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q126.39%

3.2 Future

Based on estimates for the next years, RYTM will show a very strong growth in Earnings Per Share. The EPS will grow by 37.49% on average per year.

Based on estimates for the next years, RYTM will show a very strong growth in Revenue. The Revenue will grow by 69.02% on average per year.

EPS Next Y-31.04%

EPS Next 2Y16.57%

EPS Next 3Y25.8%

EPS Next 5Y37.49%

Revenue Next Year70.31%

Revenue Next 2Y62.25%

Revenue Next 3Y67.48%

Revenue Next 5Y69.02%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RYTM. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYTM. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

RYTM's earnings are expected to grow with 25.80% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.57%

EPS Next 3Y25.8%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for RYTM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (5/16/2024, 7:15:51 PM)

After market: 39.17 0 (0%)

39.17

-0.43 (-1.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.39B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-105.88%
ROE	-444.72%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	88.38%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.36

Health

		Industry Rank	Sector Rank
Debt/Equity	1.74
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.35
Quick Ratio	4.2
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-38.21%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-31.04%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)173.49%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

RHYTHM PHARMACEUTICALS INC (RYTM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens